Home » Key Clinical Research Articles Global Medical Discovery » Prediagnostic serum levels of inflammatory biomarkers are correlated with future development of lung and esophageal cancer.

Prediagnostic serum levels of inflammatory biomarkers are correlated with future development of lung and esophageal cancer.

Significance statement

Identification of serum inflammatory biomarkers  predictive of future cancer development could potentially lead to novel strategies for early diagnosis and treatment of cancers prior to the development of clinically-apparent disease.

 

Prediagnostic serum levels of inflammatory biomarkers are correlated with future development of lung and esophageal cancer. Global Medical Discovery

 

 

 

 

 

 

Journal Reference

Keeley BR, Islami F, Pourshams A, Poustchi H, Pak JS, Brennan P, Khademi H, Genden EM, Abnet CC, Dawsey SM, Boffetta P, Malekzadeh R, Sikora AG.

Cancer Sci. 2014 ;105(9):1205-11.

Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Abstract

 While chronic inflammation is one cause of cancer, and many cancers have been shown to induce an abnormal inflammatory response, relatively few studies have looked at potential biomarkers of abnormal inflammation in patients prior to the development of cancer.  In this study by Keeley, et al, inflammatory molecules were shown to be dysregulated in the serum of patients who ultimately went on to develop esophageal and lung cancer years before clinical cancer diagnosis. Interestingly, increased levels of serum inflammatory markers were not seen in patients prior to development of head and neck cancer, which has many risk factors and characteristics in common with the other two cancers.

Go To PubMed